Baseline demographics
| Uncertain (n=23) | Appropriate (n=156) | Inappropriate (n=71) | Significance | |
|---|---|---|---|---|
| Age (years) | 54 (44–68) | 66 (57–74) | 58 (45–71) | <0.001 |
| Sex (female %) | 9 (39.1) | 92 (59) | 44 (62) | 0.14 |
| Follow-up (months) | 13.2 (12.2–18) | 12.2 (9.6–16) | 12.4 (8.5–15.6) | 0.08 |
| LVEF (%) | 60.4±8.7 | 53.2±12.7 | 59.4±7.8 | <0.001 |
| Hypertension % | 10 (43.5) | 94 (60.3) | 39 (54.9) | 0.08 |
| Diabetes % | 2 (8.7) | 46 (29.5) | 13 (18.3) | 0.04 |
| Hyperlipidaemia % | 6 (26.1) | 6 3 (40.4) | 26 (36.6) | 0.25 |
| Smoker % | 2 (8.7) | 18 (11.5) | 6 (8.5) | 0.75 |
| Family history of CAD % | 3 (13) | 23 (14.7) | 3 (4.2) | 0.06 |
| Aspirin % | 8 (34.8) | 50 (32.1) | 25 (35.2) | 0.88 |
| β-blocker % | 8 (34.8) | 46 (29.5) | 18 (25.4) | 0.83 |
| Calcium antagonist % | 3 (13) | 21 (13.5) | 5 (7) | 0.19 |
| ACE inhibitor % | 8 (34.8) | 56 (35.9) | 20 (28.2) | 0.52 |
| Statin therapy % | 6 (26.1) | 65 (41.7) | 26 (36.6) | 0.19 |
| Previous MI % | 1 (4.3) | 15 (9.6) | 5 (7) | 0.78 |
| Previous PCI % | 0 (0) | 17 (10.9) | 4 (5.6) | 0.15 |
| Previous CABG % | 1 (4.3) | 11 (7.1) | 1 (1.4) | 0.41 |
CAD, coronary artery disease; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention.